Imatinib Al

Imatinib, the active ingredient in Imatinib Al, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib targets malignant cells driven by specific tyrosine‑kinase pathways.

- Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and induces remission. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): targets the BCR‑ABL fusion protein to achieve disease control. - Gastrointestinal stromal tumor (GIST): inhibits c‑KIT and PDGFR signaling to limit tumor growth.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea - Peripheral edema - Muscle cramps or spasms - Fatigue - Diarrhea - Rash or skin irritation

Serious or Rare Side Effects: - Hepatotoxicity (elevated liver enzymes, hepatitis) - Severe neutropenia or thrombocytopenia - Cardiac failure or reduced left‑ventricular function - Pulmonary arterial hypertension - Severe skin reactions such as Stevens‑Johnson syndrome - Tumor lysis syndrome or rapid disease progression

Clinicians should consider several safety measures before and during therapy.

- Dose adjustment in hepatic impairment: reduce dose as clinically indicated. - Monitor blood counts regularly: detect cytopenias early. - Assess cardiac function: watch for signs of heart failure. - Avoid in patients with known hypersensitivity to imatinib: discontinue if reaction occurs. - Review concomitant medications for CYP3A4 interactions. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Imatinib may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase imatinib exposure. - Antacids containing aluminum or magnesium: reduce oral absorption of imatinib. - QT‑prolonging agents (e.g., sotalol): increase risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin): may lower plasma concentrations. - Warfarin: may enhance anticoagulant effect; monitor INR closely. - Live attenuated vaccines: potential reduced efficacy; consider timing of vaccination.